Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2024-04-15 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Stock Collateral Provision Agreement' (주식 담보제공 계약). It details the pledging of shares by the major shareholder to secure loans for operational funds. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for material corporate events involving major shareholders and capital structure, falling under the 'Regulatory Filings' category as it does not fit into specific categories like M&A, Earnings, or Dividends.
2024-04-15 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding a 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). This filing details the company's plan to distribute treasury shares to employees as a form of performance bonus. Since the document specifically reports the company's action regarding its own shares (disposal/buyback), it falls under the 'Transaction in Own Shares' category.
2024-04-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and contractual relationships (such as pledges and loans) of major shareholders and their special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-04-05 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from a South Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Contract for Stock Collateral Provision Involving a Change in the Largest Shareholder'. It details specific collateral agreements, debt amounts, and changes to existing collateral contracts. This type of disclosure is a standard regulatory requirement for listed companies to report significant changes in share ownership or collateralization status. Since it does not fit into specific categories like M&A, Earnings, or Dividends, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2024-04-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including acquisitions by special related parties and pledge agreements. This falls under the 'Major Shareholding Notification' category as it tracks significant ownership thresholds and changes.
2024-03-29 Korean
정기주주총회결과 (26기)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (AGM). It details the approval of financial statements, director appointments, and remuneration limits. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official outcome of the shareholder votes held on 2024-03-29.
2024-03-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.